One Minute Poster Pitches Archive

UK & Ireland Prostate Brachytherapy Conference 2024

Abstract number 1 

Outcomes for patients with prostate cancer treated with External beam radiotherapy with High dose rate brachytherapy (HDR) boost at the Dorset Cancer Centre 

Aun-Kyaw Sun, Ben Masters
University Hospital Dorset 

Purpose: To assess the outcomes including biochemical failure and toxicity for patients treated with HDR boost after setting up the technique at our centre. 

Methods: Retrospective analysis of all patients treated with HDR boost with external beam radiotherapy between April 2017 to December 2019 at the Dorset Cancer Centre. 

Results: The study included 34 patients, and among them 79% of cases were T3a grades whereas 58% were Gleason 8-10 grading and 47% were PSA >20. The data demonstrated 91% had overall 5 year biochemical free survival and overall survival with only 23% having grade 2+ toxicity. 

Conclusion: Our results are comparable to other studies showing that HDR brachytherapy boost is an effective treatment for intermediate and high risk prostate cancer. However it also confirms that it is associated with a higher rate of toxicity than external beam radiotherapy alone. 

References: 

1. Morton G, Loblaw DA, Sankreacha A et al. Single-fraction high dose rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate risk prostate cancer:an analysis of short and medium term toxicity and quality of life. Int J Radiat Oncol Biol Phys.2009 doi:10.1016/j.ijrobp.2009.05.054 
2. UK national protocol for high dose rate brachytherapy boost in prostate cancer (Peter Hoskin) 
3. RCR Radiotherapy Dose-Fractionation, third edition – prostate cancer 
4. UHD Brachytherapy protocol